Insider Trading April 1, 2026

Slide Insurance CEO Disposes of $7.07 Million in Stock While Exercising RSUs

Bruce Lucas sold 381,855 shares under a pre-arranged plan; company posts strong Q4 2025 results and launches new buyback authorization

By Nina Shah SLDE
Slide Insurance CEO Disposes of $7.07 Million in Stock While Exercising RSUs
SLDE

Slide Insurance Holdings Chief Executive Bruce Lucas sold 381,855 shares of common stock between March 30 and April 1, 2026, generating about $7.07 million through trades executed under a 10b5-1 plan. On March 31 he also sold 9,019 shares to meet tax obligations and exercised 22,919 RSUs at $0 per share. The company recently reported robust fourth-quarter 2025 results, completed a $120 million repurchase, and authorized a new $125 million buyback; analysts have raised price targets and initiated coverage with Buy and Outperform ratings.

Key Points

  • CEO Bruce Lucas sold 381,855 shares between March 30 and April 1, 2026, for about $7.07 million at $18.01 to $18.10 per share under a 10b5-1 plan.
  • On March 31 Lucas sold 9,019 shares for $162,342 to cover taxes and exercised 22,919 RSUs at $0 per share.
  • Slide Insurance reported strong Q4 2025 results - EPS $1.23 vs. $0.71 forecast and revenue of $347 million - and completed a $120 million buyback while authorizing a new $125 million program; analysts set targets between $23 and $29 and coverage changes include an Outperform and a Buy.

Bruce Lucas, Chief Executive Officer of Slide Insurance Holdings, Inc. (NYSE: SLDE), executed a series of insider transactions spanning March 30 through April 1, 2026, that resulted in the sale of 381,855 shares of the company’s common stock for approximately $7.07 million. The shares traded between $18.01 and $18.10 per share during those dispositions.

The disposition was carried out under a pre-established 10b5-1 trading plan that Lucas adopted on November 21, 2025. In a separate entry on March 31, Lucas sold an additional 9,019 shares at $18.00 per share to satisfy tax liabilities, representing proceeds of $162,342.

Also on March 31, Lucas took delivery of 22,919 shares following the exercise of restricted stock units; the exercise price reported for those awards was $0 per share.

Slide Insurance’s share price at the time of reporting stands at $17.90, below InvestingPro’s Fair Value estimate of $20.60, implying that the shares remain under that valuation benchmark despite the insider selling activity.

Recent company fundamentals and market actions provide context for the insider moves. Slide Insurance reported fourth-quarter 2025 earnings per share of $1.23, outpacing the consensus forecast of $0.71 by 73.24 percent. Revenue in the quarter was $347 million versus $238.5 million in the prior-year period. The company completed a $120 million stock repurchase program and has authorized a fresh $125 million buyback initiative.

Analyst engagement has been notable following the quarter. Keefe, Bruyette & Woods raised its price target to $23 and retained an Outperform rating, citing strong fourth-quarter outcomes and sustained strength in loss trends. Texas Capital Securities began coverage with a Buy rating and set a $25 price target. More broadly, analyst price targets mentioned in reports range from $23 to $29. InvestingPro’s assessment of Slide Insurance’s financial health is listed as "EXCELLENT," accompanied by a Pro Research Report on the stock.

The transactions and corporate developments highlight a mix of insider liquidity events and continued operational momentum. While the CEO’s sales were completed under a 10b5-1 plan and routine tax-related dispositions, the company’s recent earnings surprise, revenue growth, and capital-return programs have drawn positive analyst attention.

Risks

  • Insider selling, even when executed under a pre-arranged 10b5-1 plan, can create short-term investor uncertainty in the insurance and financials sectors due to perception effects.
  • Despite a strong quarter and buyback activity, the stock trades below InvestingPro’s Fair Value estimate of $20.60, indicating valuation uncertainty for investors focused on insurance equities.
  • Analyst price target dispersion - $23 to $29 - and reliance on continued favorable loss trends introduce forecast risk for shareholders and market participants in the insurance sector.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026